Expert Opinion on Drug Safety最新文献_第10页

Hematological toxicity of cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study. 细胞周期蛋白依赖性激酶 4/6 抑制剂对乳腺癌患者的血液学毒性：一项网络荟萃分析和药物警戒研究。

IF 3 3区医学

Expert Opinion on Drug Safety Pub Date : 2025-02-01 Epub Date: 2024-05-16 DOI: 10.1080/14740338.2024.2348566

Haiying Ding, Weiben Xu, Mengfei Dai, Shujing Li, Wenxiu Xin, Yinghui Tong, Chaoneng He, Xiufang Mi, Zhajun Zhan, Luo Fang

{"title":"Hematological toxicity of cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study.","authors":"Haiying Ding, Weiben Xu, Mengfei Dai, Shujing Li, Wenxiu Xin, Yinghui Tong, Chaoneng He, Xiufang Mi, Zhajun Zhan, Luo Fang","doi":"10.1080/14740338.2024.2348566","DOIUrl":"10.1080/14740338.2024.2348566","url":null,"abstract":"Objectives: We aimed to evaluate and compare the risk of hematological adverse events (AEs) associated with CDK4/6 inhibitors using data from randomized controlled trials (RCTs) and Food and Drug Adverse Event Reporting System (FAERS) database.Methods: The PubMed, Embase, and Cochrane Library databases were searched for RCTs related to abemaciclib, palbociclib, and ribociclib. A network meta-analysis (NMA) was conducted to compare the risks of hematological AEs, and a disproportionality analysis was performed to detect signals of hematological AEs.Results: 16 RCTs comprising 16,350 breast cancer patients were included. Palbociclib and ribociclib had similar risks for hematological AEs, except a higher risk of grade 3-4 leukopenia observed with palbociclib (risk ratio [RR]: 7.84, 95% confidence interval [95%CI]: 1.33-41.28). Abemaciclib had a higher risk of anemia than both ribociclib (grade 1-4: RR: 2.23, 95% CI: 1.25 - 3.96; grade 3-4: RR: 3.52, 95% CI: 1.59 - 8.11) and palbociclib (grade 1-4: RR: 1.65, 95%CI: 1.03 - 2.59), but a lower risk of grade 3-4 of both leukopenia (RR: 0.12, 95%CI: 0.02 - 0.49) and neutropenia (RR: 0.15, 95%CI: 0.04 - 0.52) compared with palbociclib. Signals indicating occurrence of leukopenia, neutropenia, anemia, and thrombocytopenia were identified for three CDK4/6 inhibitors.Conclusion: Abemaciclib, palbociclib, and ribociclib showed significant but inconsistent hematological toxicity risks.","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"157-165"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ocular hyperemia associated with topical glaucoma medication: understanding and differentiating clinical appearance and underlying mechanisms. 与局部青光眼药物相关的眼部充血：理解和区分临床表现和潜在机制。

IF 3 3区医学

Expert Opinion on Drug Safety Pub Date : 2025-02-01 Epub Date: 2024-12-09 DOI: 10.1080/14740338.2024.2436062

Gábor Holló

{"title":"Ocular hyperemia associated with topical glaucoma medication: understanding and differentiating clinical appearance and underlying mechanisms.","authors":"Gábor Holló","doi":"10.1080/14740338.2024.2436062","DOIUrl":"10.1080/14740338.2024.2436062","url":null,"abstract":"Introduction: Adherence to therapy is fundamental for glaucoma management. Side effects of topical intraocular pressure (IOP)-lowering medications must be managed effectively to maintain adherence to the treatment plan and avoid disease progression. Ocular hyperemia is the most common side effect of topical IOP-lowering medications. It develops either as part of the mechanism of action of an IOP-lowering medication, usually requiring no medical intervention, or as a sign of allergy or toxicity, usually requiring intervention. Therefore, differentiating between types of ocular hyperemia is clinically important.Areas covered: This clinically oriented narrative review explains the various types of topical glaucoma medication-induced ocular hyperemia, describing the underlying causes, mechanisms of development, and areas involved. Five types of ocular hyperemia associated with IOP-lowering medications are described, relating to the effects of preservatives and active ingredients in mono- and combination therapies. Relevant studies were identified through targeted searches of PubMed and Google Scholar, conducted in August 2024.Expert opinion: Clinicians should identify the type and severity of ocular hyperemia related to IOP-lowering medications and, accordingly, remove allergenic or toxic agents from therapy. Patients should be advised to continue treatment if ocular hyperemia is mild, especially if it is an expected side effect of the medication.","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"145-156"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA adverse events reporting system (FAERS).

IF 3 3区医学

Expert Opinion on Drug Safety Pub Date : 2025-02-01 DOI: 10.1080/14740338.2025.2461199

Yazed S Alsowaida, Ahmed Alsolami, Thamer A Almangour, Ivo Abraham

{"title":"Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA adverse events reporting system (FAERS).","authors":"Yazed S Alsowaida, Ahmed Alsolami, Thamer A Almangour, Ivo Abraham","doi":"10.1080/14740338.2025.2461199","DOIUrl":"10.1080/14740338.2025.2461199","url":null,"abstract":"Background: Immune and targeted anti-cancer therapies are associated with an increased risk of infectious complications. The objectives of the present study were to evaluate the infectious complications associated with immune and targeted anti-cancer drugs.Research design and methods: This was a retrospective study for immune and targeted anti-cancer drugs submitted to the FDA Adverse Event Reporting System (FAERS) from 1996 to 20 March 2024. The primary outcome was the rate of infectious disease events, and the secondary outcomes were the incidence of febrile neutropenia (FN), all-cause mortality, and the top 10 infections in each class.Results: Our study included 14 drug classes comprising 44 drugs. The incidence of infectious complications was 14.31% (110,671/773,130). The highest incidence rate was reported with IL-6 inhibitors (30.89%), the highest incidence of FN was reported with Histone deacetylase inhibitors (8.43%), and the highest all-cause mortality was reported with BCR-ABL tyrosine kinase inhibitors (17.17%).Conclusion: Immune and targeted anti-cancer therapies vary in the incidence of infectious complications. Pirtobrutinib, copanlisib, sirolimus, vorinostat, and tocilizumab were associated with high infectious complications (>30%) that warrant emphasis in the clinical guidelines. Thus, clinicians should vigilantly monitor patients undergoing immune and targeted therapies for infectious complications and use antimicrobial prophylaxes when indicated.","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-8"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biological therapies in infants and children younger than 6 years of age with atopic dermatitis: suitability and practical considerations. 婴儿和6岁以下儿童特应性皮炎的生物治疗：适用性和实用性考虑。

IF 3 3区医学

Expert Opinion on Drug Safety Pub Date : 2025-02-01 Epub Date: 2024-12-25 DOI: 10.1080/14740338.2024.2446428

Filomena Russo, Anna Rita Giampetruzzi, Maria Antonietta Pilla, Annarita Panebianco, A Dattolo, Ornella De Pità, Barbara Cocuroccia

引用次数: 0

The emerging role of Bruton's tyrosine kinase inhibition in urticaria management.

IF 3 3区医学

Expert Opinion on Drug Safety Pub Date : 2025-01-29 DOI: 10.1080/14740338.2025.2460453

Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, Mariateresa Cantelli, Maddalena Napolitano

{"title":"The emerging role of Bruton's tyrosine kinase inhibition in urticaria management.","authors":"Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, Mariateresa Cantelli, Maddalena Napolitano","doi":"10.1080/14740338.2025.2460453","DOIUrl":"10.1080/14740338.2025.2460453","url":null,"abstract":"Introduction: Bruton's tyrosine kinase (BTK) is a cytoplasmic signaling protein expressed across a variety of immune cells, terminally differentiated plasma cells, and natural killer cells. Due to the signal potential and targetable nature of BTK, the use of BTK inhibitors (BTKis) has been proposed for the management of several diseases. Currently, the use of BTKis is under investigations for several dermatological conditions such as pemphigus, systemic lupus erythematosus, hidradenitis suppurativa, atopic dermatitis, and chronic spontaneous urticaria (CSU).Areas covered: The aim of this review is to delve into the use of BTKis in the management of CSU, in order to explore the potential of therapeutic inhibition of BTK in patients with CSU. A thorough analysis of the existing medical literature was conducted across the PubMed, Ovid, Scopus, Embase, and Cochrane Library databases up to 17 August 2024.Expert opinion: BTK use may represent a breakthrough in the management of CSU. Indeed, their use is characterized by oral administration and a favorable mechanism of action that acts on a significant pathogenic pathway rather than a single molecule. However, long-term studies are needed to further investigate safety data, although data from registered trials appear to be reassuring.","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-6"},"PeriodicalIF":3.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk assessment of venetoclax-associated adverse events: a meta-analysis approach. venetoclax相关不良事件的风险评估：荟萃分析方法。

IF 3 3区医学

Expert Opinion on Drug Safety Pub Date : 2025-01-26 DOI: 10.1080/14740338.2025.2449987

Tung-Lung Wu, Chao-Kun Chen, Chien-Ming Chao, Ya-Ting Hsu, Sheng-Yen Hsiao, Teng-Song Weng

{"title":"Risk assessment of venetoclax-associated adverse events: a meta-analysis approach.","authors":"Tung-Lung Wu, Chao-Kun Chen, Chien-Ming Chao, Ya-Ting Hsu, Sheng-Yen Hsiao, Teng-Song Weng","doi":"10.1080/14740338.2025.2449987","DOIUrl":"10.1080/14740338.2025.2449987","url":null,"abstract":"Introduction: Venetoclax, an oral B-cell lymphoma-2 (BCL-2) inhibitor, shows promise in cancer treatment but has an unclear safety profile. This meta-analysis evaluates the safety of venetoclax, focusing on adverse events.Methods: Data from PubMed, Embase, Cochrane databases, and ClinicalTrials.gov were retrieved up to August 2023. Nine studies were included based on specific inclusion and exclusion criteria. A random effects model was used to calculate risk ratios (RRs) and 95% confidence intervals (CIs).Results: The meta-analysis included nine studies. Venetoclax was associated with increased risks of neutropenia (RR = 1.427, 95% CI = 1.118 to 1.822), diarrhea (RR = 1.889, 95% CI = 1.388 to 2.570), and cardiovascular events (RR = 1.726, 95% CI = 1.088 to 2.737). However, the risk of tumor lysis syndrome (TLS) with venetoclax was not increased compared to the comparators (RR = 1.478, 95% CI = 0.504 to 4.337).Conclusions: Venetoclax increases the risk of hematological, gastrointestinal, and cardiac adverse events. Clinicians should monitor these side effects, especially in patients with preexisting conditions. Further research is needed to fully understand venetoclax's safety profile.Protocol registration: https://inplasy.com/ identifier is INPLASY2023110041.","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-9"},"PeriodicalIF":3.0,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug classes associated with the development of fulminant type 1 diabetes: a retrospective analysis using the FDA adverse event reporting system database. 与暴发性1型糖尿病相关的药物类别：使用FDA不良事件报告系统数据库的回顾性分析

IF 3 3区医学

Expert Opinion on Drug Safety Pub Date : 2025-01-21 DOI: 10.1080/14740338.2024.2448202

Yang Zhou, Yupeng Chen, Shan Zhang, Zhige Wen, Zifan Zhuang, Xinyao Liu, Qing Ni

{"title":"Drug classes associated with the development of fulminant type 1 diabetes: a retrospective analysis using the FDA adverse event reporting system database.","authors":"Yang Zhou, Yupeng Chen, Shan Zhang, Zhige Wen, Zifan Zhuang, Xinyao Liu, Qing Ni","doi":"10.1080/14740338.2024.2448202","DOIUrl":"10.1080/14740338.2024.2448202","url":null,"abstract":"Background: Fulminant type 1 diabetes mellitus (FT1DM) is a severe subtype of type 1 diabetes characterized by rapid onset, metabolic disturbances, and irreversible insulin secretion failure. Recent studies have suggested associations between FT1DM and certain medications, warranting further investigation.Objectives: This study aims to identify drugs associated with an increased risk of FT1DM using the FDA Adverse Event Reporting System (FAERS) database, evaluate reporting patterns, and provide actionable insights to reduce FT1DM occurrence and improve medication safety.Methods: A retrospective analysis of FAERS data from 2013 to 2023 was conducted. Drug names were standardized using text mining tools, and safety signals were evaluated using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).Results: A total of 706 FT1DM cases were identified, predominantly in older individuals and males. Nineteen drugs were implicated, including immune checkpoint inhibitors (nivolumab, ipilimumab, pembrolizumab, avelumab, durvalumab, atezolizumab), lenvatinib, eribulin, psychiatric drugs (atomoxetine, carbamazepine, lamotrigine), anti-infectives (sulfamethoxazole, trimethoprim, amoxicillin), and metabolic modulators (dapagliflozin, sitagliptin, hydrochlorothiazide, allopurinol).Conclusion: This study highlights drugs potentially triggering FT1DM and emphasizes the need for pharmacovigilance and glucose monitoring in patients treated with these medications.","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-7"},"PeriodicalIF":3.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142964379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A pharmacovigilance study on the safety of faricimab in real-world scenario using FDA adverse event reporting system database. 利用FDA不良事件报告系统数据库对法利昔单抗在现实情况下的安全性进行药物警戒研究。

IF 3 3区医学

Expert Opinion on Drug Safety Pub Date : 2025-01-21 DOI: 10.1080/14740338.2025.2456173

Furong Han, Xiang Li, Tao Tao, Jiawei Wang

{"title":"A pharmacovigilance study on the safety of faricimab in real-world scenario using FDA adverse event reporting system database.","authors":"Furong Han, Xiang Li, Tao Tao, Jiawei Wang","doi":"10.1080/14740338.2025.2456173","DOIUrl":"https://doi.org/10.1080/14740338.2025.2456173","url":null,"abstract":"Background: Faricimab is predominantly prescribed for conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema related to retinal vein occlusion (RVO-ME). Currently, a notable absence of large-scale, real-world studies focusing on the adverse reactions of faricimab exists.Methods: This study assesses the side effects of faricimab by analyzing reports of adverse events (AEs) from the FDA's AE Reporting System (FAERS) database. Through disproportionality analysis, this study substantiates the drug's safety oversight.Results: Our study revealed 2,746 instances of adverse events linked to faricimab, spanning 21 system organ classes (SOCs). The study retained 121 significant disproportionality preferred terms (PTs) that met criteria across all four analytical methods. Faricimab-associated AEs not documented in the drug instructions included visual impairment, blindness, retinal hemorrhage, anterior chamber inflammation, keratic precipitates, dry eye, chorioretinitis, diabetic retinopathy, and others.Conclusion: The majority of our results align with earlier clinical studies and the details outlined in the product's manual. Additionally, we identified several unforeseen and potential AE signals related to faricimab use. These insights are instrumental for ongoing clinical surveillance and risk assessment associated with the drug.","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-8"},"PeriodicalIF":3.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the safety profile of amivantamab based on real-world evidence: a call to vigilance. 基于真实世界证据的阿米万他抗安全性评估：提高警惕的呼吁。

IF 3 3区医学

Expert Opinion on Drug Safety Pub Date : 2025-01-20 DOI: 10.1080/14740338.2025.2456167

Zuyue Liao, Cheng Luo, Yinghua Huang, Zhongcai Jiang, Hongqun Wei, Yu Wang

{"title":"Evaluation of the safety profile of amivantamab based on real-world evidence: a call to vigilance.","authors":"Zuyue Liao, Cheng Luo, Yinghua Huang, Zhongcai Jiang, Hongqun Wei, Yu Wang","doi":"10.1080/14740338.2025.2456167","DOIUrl":"10.1080/14740338.2025.2456167","url":null,"abstract":"Background: Amivantamab has been approved for EGFR exon 20 insertion-mutated non-small-cell lung cancer. The aim of this study was to perform an in-depth analysis of its safety profile.Research design and methods: Safety reports were collected from the database of the Food and Drug Administration Adverse Event Reporting System from April 2021 to September 2023, and the reporting odds ratio (ROR) method was used to detect potential safety signals. Mobocertinib, an agent with similar properties to amivantamab, served as a control for comparison.Results: A total of 88 safety signals were detected, most of which were novel. In comparison with mobocertinib, amivantamab appeared to cause more injury, poisoning, and procedural complications (ROR = 15.54, 95% CI 10.25-23.58); respiratory, thoracic, and mediastinal disorders (ROR = 1.92, 95% CI 1.57-2.34); infections and infestations (ROR = 1.39, 95% CI 1.09-1.76); blood and lymphatic system disorders (ROR = 9.57, 95% CI 6.17-14.84); and immune system disorders (ROR = 6.41, 95% CI 3.14-13.12). Moreover, amivantamab was associated with higher risks of thrombosis events, bone marrow suppression, skin and soft tissue infection, deterioration of respiratory symptoms, and noninfectious pneumonitis.Conclusion: The safety profile of amivantamab requires attention; particularly, monitoring of the adverse drug events described above is necessary during its administration.","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-10"},"PeriodicalIF":3.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hematological toxicities in antibody-drug conjugates related with breast cancer: a pharmacovigilance study using FDA adverse event reporting system database. 与乳腺癌相关的抗体-药物偶联物的血液学毒性：使用FDA不良事件报告系统数据库的药物警戒研究。

IF 3 3区医学

Expert Opinion on Drug Safety Pub Date : 2025-01-08 DOI: 10.1080/14740338.2025.2449991

Shiqiao Wang, Heng Pan, Zhiru Chen, Hui Zhou, Jiayi Chen, Guosheng Zou, Jiayu Huang, Qinghua Mei

{"title":"Hematological toxicities in antibody-drug conjugates related with breast cancer: a pharmacovigilance study using FDA adverse event reporting system database.","authors":"Shiqiao Wang, Heng Pan, Zhiru Chen, Hui Zhou, Jiayi Chen, Guosheng Zou, Jiayu Huang, Qinghua Mei","doi":"10.1080/14740338.2025.2449991","DOIUrl":"https://doi.org/10.1080/14740338.2025.2449991","url":null,"abstract":"Objective: The trastuzumab emtansine, trastuzumab deruxtecan, and sacituzumab govitecan are antibody-drug conjugates (ADCs) that have demonstrated efficacy in the treatment of breast cancer. Nonetheless, these ADCs can also induce severe toxicities in various organ systems, particularly the hematological system. Therefore, this study evaluated the hematological toxicities associated with ADCs in breast cancer based on real-world data.Methods: Data were extracted from the FDA Adverse Event Reporting System (FAERS) database, spanning from 2014 Q1 to 2023 Q3. Further analysis was done on the hematological toxicities related with ADCs, including their features, onset time, and fatality proportion.Results: Out of 10,976 adverse event reports, 1895 hematotoxicity reports (17.26%) were analyzed. All ADCs exhibited positive safety signals for hematological toxicities, as indicated by reporting odds ratios and the information component. Unexpected significant adverse events, including splenomegaly, immune thrombocytopenia, hemolytic anemia, and hemolytic anemia, that were discovered in the medication label transpired during our data mining. The median time-to-onset of these toxicities was 13 days (interquartile range [IQR] 7-54.75), and the fatality proportion associated with hematological toxicities and ADCs was 17.41%.Conclusion: The study indicated that hematological toxicities caused by ADCs preferentially emerge early and may have catastrophic consequences. Early detection and management of these hematological toxicities associated with ADC is essential.","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-9"},"PeriodicalIF":3.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0